The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound.
Bluebird Bio’s Thalassemia Gene Therapy Under Priority Review With FDA
The FDA has accepted Bluebird bio Inc’s (NASDAQ:BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has granted priority…
64 Biggest Movers From Yesterday
Gainers
Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle charging solutions for a full range of applications.
Goldman Sachs Downgrades bluebird bio to Sell, Lowers Price Target to $10
Goldman Sachs analyst Salveen Richter downgrades bluebird bio (NASDAQ:BLUE) from Neutral to Sell and lowers the price target from $23 to $10.
Barclays Maintains Equal-Weight on bluebird bio, Lowers Price Target to $13
Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $20 to $13.
Morgan Stanley Downgrades bluebird bio to Underweight, Announces $11 Price Target
Morgan Stanley analyst Matthew Harrison downgrades bluebird bio (NASDAQ:BLUE) from Equal-Weight to Underweight and announces $11 price target.
64 Stocks Moving In Friday’s Mid-Day Session
Gainers
Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the estimated price range of $4-$6, for raising gross proceeds of $10 million.